Calculate This Peptides · Selank
Module · Peptides

Selank
Dosage

Mix a vial of selank with bacteriostatic water and this gives the concentration, the syringe units for your dose, and what every mark on the syringe holds. Dose is something you enter, not something this suggests.

See the math behind this calculator
U-100 syringe
1 mL = 100 units

Milligram
= 1000 mcg

Water added
sets concentration
The vial
Your dose
Draw to -

On your syringe
0-50
Concentration-
One unit holds-
Doses in the vial-
Doses run out in-
What each mark holds
Syringe markVolumeSelank

What selank is

Selank is a peptide of seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro. One abstract describes it as a synthetic derivative of tuftsin, a peptide of four amino acids that the body makes. Another says selank's active component includes tuftsin and three more natural amino acids. FDA lists it as selank acetate and also calls it TP-7.

This page doesn't give a molecular weight, because none of the documents it rests on states one. The calculator doesn't need it.

Where it stands with the FDA

This page found no FDA-approved selank product. A search of DailyMed, the National Library of Medicine's database of drug labels, returned no labels for selank when it was run for this page in October 2026.

Selank reached the FDA as selank acetate, nominated for use in compounding. FDA placed it in category 2, the group it keeps for substances that may present significant safety risks. The nominators later withdrew it. FDA's list of substances nominated under section 503A, updated May 14, 2026, doesn't have it in any category.

FDA's page on category 2, current as of April 22, 2026, still gives the potential risk it identified. It says compounded drugs containing selank acetate may pose a risk of immunogenicity, which is an immune reaction to the drug, for certain routes of administration, because of the potential for aggregation and peptide-related impurities. It also says FDA lacks important information regarding any safety issues raised by selank acetate administered to humans.

This page found no FDA review of selank like the ones the agency has published for semax and other peptides. FDA's review of semax for the July 23-24, 2026 meeting of its Pharmacy Compounding Advisory Committee says an article about selank, which it calls a different peptide, is out of the scope of that evaluation. Selank isn't named on the page for that meeting, or in the minutes of the committee's meetings on October 29, 2024 and December 4, 2024, so this page has no vote to report.

What the published studies compared

This page read the PubMed abstracts of three studies that gave selank to patients. All three papers are in Russian, in the same journal, so only the abstracts were read.

A 2008 paper studied 62 patients with generalized anxiety disorder and neurasthenia. The effect of selank in 30 patients was compared with that of medazepam in 32. The abstract says the anxiolytic effects of both drugs were similar.

A 2014 paper compared selank with phenazepam in 60 patients with phobic-anxiety and somatoform disorders. Its abstract says pronounced anxiolytic and mild nootropic effects of selank were demonstrated.

A 2015 paper compared phenazepam alone, in 30 patients, with selank and phenazepam together, in 40 patients. Its abstract says the combined treatment decreased the level of phenazepam's undesirable side effects.

None of the three abstracts says the study was randomized, blinded or placebo-controlled, and none reports side effects of selank itself.

None of the three abstracts states the dose that was given or how it was given, so this page doesn't either. An abstract is the authors' own short account of a paper. It isn't an FDA finding, and FDA says it lacks important information on safety issues raised by selank acetate in humans.

Storing selank

None of the documents this page rests on gives a storage temperature for selank or says how long it keeps, so this page doesn't either.

The DailyMed search found no label for selank, so nothing official says how long a mixed vial keeps.

Selank dosage calculator questions

How do I turn a selank dose into syringe units?

Divide the dose by the concentration to get millilitres, then multiply by 100. A 5 mg vial mixed with 2 mL is 2.5 mg/mL, so one unit on an insulin syringe holds 25 mcg and ten units hold 250 mcg.

How much bacteriostatic water goes in a 5 mg vial of selank?

There's no single right amount. The water only sets the concentration, and the amount of selank in the vial stays the same. With 5 mg, 1 mL makes 5 mg/mL, 2 mL makes 2.5 mg/mL and 3 mL makes 1.667 mg/mL. Choose the amount that puts your dose somewhere between about 10 and 40 units, where it's easiest to read.

Is selank approved by the FDA?

Not that this page could find. A search of DailyMed, the National Library of Medicine's database of drug labels, returned no labels for selank. Selank acetate was nominated for use in compounded drugs and FDA placed it in category 2, its group for substances that may present significant safety risks. The nominators later withdrew it.

Does this page tell me how much selank to take?

No. This page found no FDA-approved selank product, so it has no approved dose to point to, and the abstracts of the three studies in patients don't state one. The dose box starts empty for that reason, and the chart only converts.

Does this calculator work for a semax and selank blend?

No. It works out one peptide in a vial and can't split a blend. FDA's review of semax says semax products are marketed in combination with selank, and describes one website offering a 50:50 combination of the two as a 2.5 mg/mL injectable product and a 1.25 mg/mL nasal spray. That's a report of what one website offered, not a strength FDA reviewed.

Is selank the same thing as TP-7?

FDA's page lists the substance as selank acetate (TP-7), so TP-7 is another name the agency uses for it.

More peptide calculators by name

The same instrument, set up one peptide at a time. For any other vial, use the peptide reconstitution calculator.

Show the working

Four divisions and a unit conversion, with your own numbers filled in below. If any of it looks wrong, it might be, so tell us what we got wrong.

Concentration after mixing mg per mL = vial mg ÷ water mL
What one syringe unit holds mg per unit = mg per mL ÷ 100
Volume to draw, and the units that's mL = dose mg ÷ mg per mL units = mL × 100
Doses in the vial, and how long it lasts doses = vial mg ÷ dose mg days = doses ÷ doses per day

Constants used

  • 1000 micrograms in a milligram
  • 100 units = 1 mL, the insulin syringe calibration, identical on 0.3, 0.5 and 1.0 mL barrels
  • 10 to 40 units is the band this page treats as comfortable to measure. That's a judgement, not a standard

Note what isn't here. This page has no dose recommendation, potency assumption or half-life. The vial and water boxes start empty, because this page can't know what your vial holds, and the vial sizes in its examples are only examples. The math also treats the water you add as the final volume. Powder takes up a little room of its own, which matters for vials holding a lot of it.

The sources

The arithmetic on this page is exact and needs no source. Everything it says about selank does, and it comes from the FDA's own pages and documents, a search of DailyMed, and the PubMed abstracts of published papers.

  1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of April 22, 2026. That selank acetate (TP-7) was nominated, placed in category 2 and withdrawn by the nominators, and the potential safety risk FDA identified.
  2. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026. FDA's running list of nominated substances and its three categories. Checked for selank and TP-7 by name; neither is in any of them.
  3. FDA Briefing Document for Semax-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. That FDA treats selank as a different peptide outside that review, and its report of a website selling a semax and selank combination.
  4. DailyMed, National Library of Medicine. Search results for selank, run October 3, 2026. That a search of the label database for selank returned no labels.
  5. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018. PubMed abstract. The amino acid sequence, and that selank is a heptapeptide.
  6. Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. Experimental optimization of learning and memory processes by selank. Eksp Klin Farmakol. 2010. PubMed abstract. That selank is a synthetic derivative of tuftsin, a tetrapeptide the body makes.
  7. Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskii II, Zakharova NM, Andreeva LA. Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia. Neurosci Behav Physiol. 2008. PubMed abstract. That selank's active component includes tuftsin and three more amino acids.
  8. Zozulia AA, Neznamov GG, Siuniakov TS, and others. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed abstract. The 2008 comparison with medazepam: who was studied and what the abstract reports.
  9. Medvedev VE, Tereshchenko ON, Israelian AIu, and others. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PubMed abstract. The 2014 comparison with phenazepam: who was studied and what the abstract reports.
  10. Medvedev VE, Tereshchenko ON, Kost NV, and others. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PubMed abstract. The 2015 comparison of phenazepam alone with selank and phenazepam together.
  11. FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. The meeting page: which substances were discussed on which day and for what use. No minutes were posted when this page was written.
  12. FDA. Final Summary Minutes, Pharmacy Compounding Advisory Committee, October 29, 2024. The committee's recorded votes and the reasons members gave.
  13. FDA. Final Summary Minutes, Pharmacy Compounding Advisory Committee, December 4, 2024. The committee's recorded votes and the reasons members gave.
  14. Humulin R U-100 label - DailyMed, National Library of Medicine. The syringe scale this page converts into: 100 units per mL, the same on 0.3, 0.5 and 1.0 mL barrels.

None of these documents contains a dose recommendation that applies to you, and neither does this page. They're listed so every statement here can be checked against where it came from.